Prior failed checkpoint inhibitor clinical trials

Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In

This study looks at new treatments for advanced lung cancer that has stopped responding to previous therapies. It compares a new drug combination with standard chemotherapy to see if it's more effective and safe for patients who have already tried other treatments.